Trial Profile
Randomized, Phase II Study Evaluating Concurrent or Sequential Fixed-Dose Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin; Ropidoxuridine
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Oct 2023 Updated results at 4-years and tumor-immune correlates presented at the 48th European Society for Medical Oncology Congress.
- 06 Sep 2023 Planned End Date changed from 1 Jun 2026 to 30 Jun 2026.
- 15 Sep 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2026.